SCHEDULE: Clearline Capital Discloses 6.7% Stake in Heron Therapeutics
Beneficial Ownership Disclosure
Clearline Capital LP, Clearline Capital LLC, and Marc Majzner have jointly disclosed a 6.7% beneficial ownership stake in Heron Therapeutics, Inc.
Summary
- Clearline Capital LP, Clearline Capital LLC, and Marc Majzner collectively reported beneficial ownership of 12,235,239 shares of Heron Therapeutics, Inc. common stock.
- This represents 6.7% of the outstanding common stock of Heron Therapeutics, Inc.
- The ownership percentage is based on 183,362,522 common shares reported as issued and outstanding as of October 30, 2025, in the Issuer's Quarterly Report on Form 10-Q.
- The reporting persons hold shared voting power and shared dispositive power over all 12,235,239 shares.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant institutional stake can imply confidence in the company's long-term prospects, even without an explicit intent to influence control.
Positives
- A significant institutional investor, Clearline Capital, has taken a 6.7% stake in Heron Therapeutics, indicating potential confidence in the company's future prospects.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that institutional filings like this often signal increased scrutiny or potential activist interest, though this 13G explicitly states no intent to influence control. For a biotech company like Heron Therapeutics, institutional backing can be crucial for stability and future funding.
Stakeholder Impact
- Shareholders: Increased institutional ownership may provide a perception of stability and confidence in the company's stock.
Key Dates
| Date | Description |
|---|---|
| 10/30/2025 | Date as of which Heron Therapeutics, Inc. reported 183,362,522 common shares issued and outstanding in its Form 10-Q. |
| 12/31/2025 | Date of event requiring the filing of this statement (beneficial ownership exceeding 5%). |
| 02/17/2026 | Date of signing and filing of the Schedule 13G and Joint Filing Agreement. |
Recommendation
holdThe filing indicates a significant institutional stake, which can be a positive signal. However, without additional financial or operational details from Heron Therapeutics, a "hold" recommendation is prudent, acknowledging the institutional confidence while awaiting further company-specific news.
Keywords
Heron Therapeutics, HTBX, Clearline Capital, Schedule 13G, beneficial ownership, institutional investment, common stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.